Apogee: Phase 2 APG777 hits all endpoints; EASI-75 66.9% (42.5% placebo-adjusted), safety favorable

Apogee Therapeutics, Inc.

APEX Part A met primary endpoint: 71% mean EASI reduction vs 33.8% placebo (p<0.001).
EASI-75 achieved by 66.9% of APG777 patients vs 24.6% placebo (p<0.001); highest of any biologic in global study.
Rapid itch relief: 50.7% reduction in Itch NRS at Week 1 (p<0.01). Safety well-tolerated, no injection site reactions.
Exposure-response: top quartiles had 83-89% EASI-75; Part B testing higher dose, readout mid-2026.
52-week maintenance data expected 1H 2026; APG279 Phase 1b vs DUPIXENT dosed, readout 2H 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.